Plain-English translation of NCT04991103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of four medications—daratumumab, bortezomib, dexamethasone, lenalidomide, and cyclophosphamide—to treat newly diagnosed multiple myeloma and a related blood disorder called AL amyloidosis. The goal is to see whether this medication combination works well enough that some patients might not need a stem cell transplant, which is a more intensive procedure with serious side effects.
Stem cell transplant has long been standard treatment for blood cancers, but it carries real risks including infections, organ damage, and long-term health problems. Researchers want to know if this new four-drug combination can work so effectively that some patients can safely skip or delay transplant, improving their quality of life.
You likely qualify if…
You likely don't qualify if…
You will receive the four-medication combination on a treatment schedule set by the study team, likely involving clinic visits for infusions and monitoring blood work. Your doctors will watch how well the medication works by checking for minimal residual disease (leftover cancer cells not visible to standard tests) to decide whether you need a stem cell transplant later. The study involves close follow-up with lab tests and imaging to track your response.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States